drugset / Trial / NCT01351168
Use of Zolpidem in Parkinson's Disease
RandomizedCrossoverQuadruple-blindTreatment
Summary
Levodopa treatment is associated with long-term complications. Dopamine deficiency is associated with abnormal activity in certain parts of the brain. Zolpidem may change this abnormal activity and, by doing so, may work in a different way than levodopa to help parkinsonism. The working hypothesis for this aim is that ZLP is superior to placebo in acutely improving motor symptoms of PD. The investigators will conduct a randomized,controlled, double-blind, cross-over study in 40 patients with PD. Each patient will receive placebo, levodopa and 2 doses of ZLP in a randomized order on 4 different occasions, about one week apart.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Levodopa | Small molecule | 200 mg | Oral |
| Subject | Zolpidem | Small molecule | 7.5 mg | Oral |
| Subject | Zolpidem | Small molecule | 10 mg | Oral |
| Subject | Zolpidem | Small molecule | 15 mg | Oral |